Authorization may be granted for the following indications with the specified durations and conditions
Multifocal Motor Neuropathy (MMN): Listed as an indication
Authorization details appear elsewhere in document
Hematophagocytic Lymphohistiocytosis (HLH) or Macrophage Activation Syndrome (MAS): Authorization of 6 months may be granted for treatment of hypogammaglobulinemia in HLH or MAS when total IgG is less than 400 mg/dL or two standard deviations below the mean for age.IgG < 400 mg/dL or 2 SD below mean for age
6 months authorization
Hemolytic Disease of the Newborn: Authorization of 6 months may be granted for isoimmune hemolytic disease in neonates.
6 months authorization
HIV-associated Thrombocytopenia (pediatrics): Authorization of 6 months may be granted for pediatric members with IgG < 400 mg/dL and one of listed clinical conditions (recurrent bacterial infections despite prophylaxis; measles vaccination with residence in high-prevalence region; thrombocytopenia despite ART; chronic bronchiectasis; T4 count ≥ 200/mm3).IgG < 400 mg/dL; T4 ≥ 200/mm3
6 months authorization
HIV-associated Thrombocytopenia (adults): Authorization of 6 months may be granted for adult members with significant bleeding, platelet count < 20,000/mcL, and failure of RhIG in Rh-positive patients.platelet < 20,000/mcL
6 months authorization
Hyperimmunoglobulinemia E Syndrome: Authorization of 6 months may be granted to treat severe eczema in hyperimmunoglobulinemia E syndrome.
6 months authorization
Hypogammaglobulinemia from CAR-T therapy: Authorization of 6 months may be granted for members with IgG < 400 mg/dL receiving CAR-T therapy (examples of CAR-T agents listed).IgG < 400 mg/dL
6 months authorization
Multiple Myeloma: Authorization of 6 months may be granted for multiple myeloma in members who have recurrent, serious infections despite the use of prophylactic antibiotics.recurrent serious infections despite prophylactic antibiotics
6 months authorization
Neonatal Hemochromatosis (prophylaxis during pregnancy): Authorization of 6 months may be granted for prophylaxis in members who are pregnant with a history of pregnancy ending in documented neonatal hemochromatosis.history of pregnancy ending in documented neonatal hemochromatosis
6 months authorization
Opsoclonus-myoclonus: Authorization of 6 months may be granted for paraneoplastic opsoclonus-myoclonus-ataxia associated with neuroblastoma or refractory opsoclonus-myoclonus as last-resort treatment.refractory or paraneoplastic association
6 months authorization
Post-transfusion Purpura: Authorization of 1 month may be granted for post-transfusion purpura.
1 month authorization
Rasmussen Encephalitis: Authorization of 6 months may be granted for members whose symptoms do not improve with anti-epileptic drugs and corticosteroids.failure to improve with AEDs and corticosteroids
6 months authorization
Renal Transplantation (ABO incompatible or positive crossmatch): Authorization of 6 months may be granted for a member undergoing renal transplantation from a live donor with ABO incompatibility or positive cross match.ABO incompatibility or positive crossmatch
6 months authorization
Secondary Immunosuppression (major surgery, hematologic malignancy, burns, collagen-vascular disease): Authorization of 6 months may be granted to prevent or modify recurrent bacterial or viral infections in members with secondary immunosuppression and IgG < 400 mg/dL associated with listed causes.IgG < 400 mg/dL
6 months authorization
Solid Organ Transplantation (allosensitized): Authorization of 6 months may be granted for solid organ transplantation for allosensitized members.allosensitization status
6 months authorization
Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome: Authorization of 1 month may be granted for severe cases.severe cases
1 month authorization
Toxic Shock Syndrome: Authorization of 1 month may be granted for staphylococcal or streptococcal toxic shock syndrome when infection is refractory to several hours of aggressive therapy, an undrainable focus is present, or member has persistent oliguria with pulmonary edema.refractory infection or undrainable focus or persistent oliguria with pulmonary edema
1 month authorization
Systemic Lupus Erythematosus (severe, active): Authorization of 6 months may be granted for severe, active SLE in members who have experienced inadequate response, intolerance or contraindication to first- and second-line therapies.inadequate response/intolerance/contraindication to 1st- and 2nd-line therapies
6 months authorization
Toxic Necrotizing Fasciitis Due To Group A Streptococcus: Authorization of 1 month may be granted for members with fasciitis due to invasive streptococcal infection.invasive streptococcal infection causing fasciitis
1 month authorization